Nuestros investigadores

Lidia Sancho Rodriguez

Publicaciones científicas más recientes (desde 2010)

Autores: Morales, María Isabel, (Autor de correspondencia); Ornilla, Enrique Tomás; Sancho, Lidia; et al.
Revista: REUMATOLOGIA CLINICA
ISSN 1699-258X  Vol. 15  Nº 5  2019  págs. 307 - 308
Autores: Prieto, Elena; Garcia-Velloso, Maria Jose; Rodríguez-Fraile, M; et al.
Revista: PHYSICA MEDICA
ISSN 1120-1797  Vol. 46  2018  págs. 134-139
A significant radiation dose reduction of 28.7% was reached. Despite a slight reduction in image quality, the new regime was successfully implemented with readers reporting unchanged clinical confidence
Autores: Bilbao, José Ignacio; Sancho, Lidia; et al.
Revista: JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
ISSN 1051-0443  Vol. 29  Nº 9  2018  págs. 1305 - 1306
Autores: Grisanti, F; García, Berta; Morales, María Isabel; et al.
Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
ISSN 2253-654X  Vol. 37  Nº Supl 1  2018  págs. 87
Autores: Marti-Climent, JM; Prieto, Elena; Morán, Verónica; et al.
Revista: EJNMMI RESEARCH
ISSN 2191-219X  Vol. 7  Nº 1  2017  págs. 37
The mean ED for body and brain PET/CT protocols with different radiopharmaceuticals ranged between 4.6 and 20.0 mSv. The major contributor to total ED for body protocols is CT, whereas for brain studies, it is the PET radiopharmaceutical.
Autores: Sancho, Lidia; Rodríguez-Fraile, M; Bilbao, José Ignacio; et al.
Revista: JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
ISSN 1051-0443  Vol. 28  Nº 11  2017  págs. 1536 - 1542
Purpose:To determine if baseline patient, tumor, and pretreatment evaluation characteristics could help identify patients who require technetium-99m (Tc-99m) macroaggregated albumin Tc-(99m MAA) imaging before selective internal radiation therapy (SIRT). Materials and Methods: In this retrospective analysis, 532 consecutive patients with primary (n = 248) or metastatic (n = 284) liver tumors were evaluated between 2006 and 2015. Variables were compared between patients in whom Tc-99m MAA imaging results contraindicated/modified SIRT administration with yttrium-90 (Y-90) resin microspheres and those who were treated as initially planned. The Tc-99m MAA findings that contraindicated/modified SIRT were a lung shunt fraction (LSF) > 20%, gastrointestinal Tc-99m MAA uptake, or a mismatch between Tc-99m MAA uptake and intrahepatic tumor distribution. Results: LSF > 20% and gastrointestinal MAA uptake were observed in 7.5% and 3.9% of patients, respectively, and 11% presented a mismatch. Presence of a single lesion (odds ratio [OR] = 2.4) and vascular invasion (OR = 5.5) predicted LSF > 20%, and GI MAA uptake was predicted by the presence of liver metastases (OR = 3.7) and Tc-99m MAA injection through the common/proper hepatic artery (OR = 4.7). Vascular invasion (OR = 4.1) was the only predictor of LSF > 20% and/or GI MAA uptake (sensitivity = 49.2%, specificity = 80.3%, negative predictive value = 92.4%). Previous antiangiogenic treatment (OR = 2.4) and presence of a single lesion (OR = 2.6) predicted mismatch. Conclusions: Imaging with Tc-99m MAA is essential in SIRT workup because baseline characteristics may not adequately predict Tc-99m MAA results. Nevertheless, the absence of vascular invasion potentially identifies a group of patients at low risk of SIRT contraindication/modification in whom performing SIRT in a single session (ie, pretreatment evaluation and SIRT on the same day) should be explored.
Autores: Garcia-Velloso, Maria Jose; Rodríguez-Fraile, M; et al.
Revista: EUROPEAN RADIOLOGY
ISSN 0938-7994  Vol. 27  Nº 8  2017  págs. 3190-3198
Our aim was to evaluate the diagnostic accuracy of magnetic resonance imaging (MRI) fused with prone 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) in primary tumour staging of patients with breast cancer. METHODS: This retrospective study evaluated 45 women with 49 pathologically proven breast carcinomas. MRI and prone PET-CT scans with time-of-flight and point-spread-function reconstruction were performed with the same dedicated breast coil. The studies were assessed by a radiologist and a nuclear medicine physician, and evaluation of fused images was made by consensus. The final diagnosis was based on pathology (90 lesions) or follow-up¿¿¿24 months (17 lesions). RESULTS: The study assessed 72 malignant and 35 benign lesions with a median size of 1.8 cm (range 0.3-8.4 cm): 31 focal, nine multifocal and nine multicentric cases. In lesion-by-lesion analysis, sensitivity, specificity, positive and negative predictive values were 97%, 80%, 91% and 93% for MRI, 96%, 71%, 87%, and 89% for prone PET, and 97%. 94%, 97% and 94% for MRI fused with PET. Areas under the curve (AUC) were 0.953, 0.850, and 0.983, respectively (p¿<¿0.01). CONCLUSIONS: MRI fused with FDG-PET is more accurate than FDG-PET in primary tumour staging of breast cancer patients and increases the specificity of MRI.
Autores: Guillen Valderrama, E; Díaz Perdigón, M.; García, Berta; et al.
Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
ISSN 2253-654X  Vol. 36  Nº Supl 1  2017  págs. 16
Autores: Garcia-Velloso, Maria Jose; Bastarrika, Gorka; de Torres, Juan Pablo; et al.
Revista: LUNG CANCER
ISSN 0169-5002  Vol. 97  2016  págs. 81-86
A major drawback of lung cancer screening programs is the high frequency of false-positive findings on computed tomography (CT). We investigated the accuracy of selective 2-[fluorine-18]-fluoro-2-deoxy-d-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scan in assessing radiologically indeterminate lung nodules detected in lung cancer screening. Methods: FDG PET/CT was performed to characterize 64 baseline lung nodules >10 mm and 36 incidence nodules detected on low-dose CT screening in asymptomatic current or former smokers (83 men, age range 40¿83 years) at high risk for lung cancer. CT images were acquired without intravenous contrast. Nodules were analyzed by size, density, and metabolic activity and visual scored on a 5-point scale for FDG uptake. Nodules were classified as negative for malignancy when no FDG uptake was observed, or positive when focal uptake was observed in the visual analysis, and the maximum standardized uptake value (SUVmax) was measured. Final diagnosis was based on histopathological evaluation or at least 24 months of follow-up. Results: A total of 100 nodules were included. The prevalence of lung cancer was 1%. The sensitivity, specificity, NPV and PPV of visual analysis to detect malignancy were 84%, 95%, 91%, and 91%, respectively, with an accuracy of 91% (AUC 0.893). FDG PET/CT accurately detected 31 malignant tumors (diameters 9¿42 mm, SUVmax range 0.6¿14.2) and was falsely negative in 6 patients. With SUVmax threshold
Autores: Sancho, Lidia; Rodríguez-Fraile, M; Prieto, Elena; et al.
Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
ISSN 1619-7070  Vol. 43  Nº Suppl. 1  2016  págs. S12 - S12
Autores: Prieto, Elena; Morán, Verónica; García, Berta; et al.
Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
ISSN 1619-7070  Vol. 43  Nº Supl.1  2016  págs. S528 - S528
Autores: Rodríguez-Fraile, M; Sancho, Lidia; Guillén-Grima, F; et al.
Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
ISSN 1619-7070  Vol. 43  2016  págs. S329 - S329
Autores: Morán, Verónica; Prieto, Elena; Zubiria, A.; et al.
Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
ISSN 1619-7070  Vol. 43  Nº Supl 1  2016  págs. S410
Autores: Prieto, Elena; Marti-Climent, JM; Morán, Verónica; et al.
Revista: PHYSICA MEDICA
ISSN 1120-1797  Vol. 31  Nº 8  2015  págs. 948-955
Optimization of reconstruction algorithm and parameters has been performed to take particular advantage of the last generation PET scanner, recommending specific settings for different brain PET radiotracers.
Autores: Sancho, Lidia; Guillen Valderrama, E; Garcia-Velloso, Maria Jose; et al.
Revista: JOURNAL OF NUCLEAR MEDICINE
ISSN 0161-5505  Vol. 56  Nº Supl.3  2015  págs. 1273
Autores: Pérez-Pevida, Belén; Sancho, Lidia; Guillen Valderrama, E; et al.
Revista: DIABETOLOGIA
ISSN 0012-186X  Vol. 58  Nº Supl. 1  2015  págs. 342
Autores: Sancho, Lidia; Morán, Verónica; et al.
Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
ISSN 2253-8070  Vol. 34  Nº Supl. 1  2015  págs. 59
La evaluación clínica del PET de amiloide con 18 F-florbetapir no se afecta por el tipo de equipo, aunque los de nueva generación reducen el número de casos dudosos. Para el seguimiento, los estudios deben ser adquiridos en un tiempo de adquisición similar. Estos hallazgos son relevantes para los ensayos de posibles nuevos fármacos anti-amiloid
Autores: Sancho, Lidia; Guillen Valderrama, E; Pérez-Pevida, Belén; et al.
Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
ISSN 2253-8070  Vol. 34  Nº Supl.1  2015  págs. 79
Conclusiones: La interrupción de M 48h fue mejor que 24h para la reducción de la CI de 18F-FDG en pacientes con DM2 y mejoró significativamente la calidad de los estudios 18F-FDG-PET/CT. Aunque la glucemia aumentó tras la interrupción de M, permaneció en rangos aceptables.